Tell your story and become a face of migraine.
Continue Reading
PBAC decision on Ajovy deferred
PBAC has decided to defer their decision on Ajovy, but it’s not a ‘no’.
Continue ReadingAimovig, Emgality and Ajovy are all now available on private script
All three CGRP antagonist monoclonal antibodies, Aimovig, Emgality and Ajovy, are all now available with a private prescription.
Continue Reading
Starting to make some noise
Let’s start getting heard.
Continue Reading
Disappointed but we get it: Aimovig pulls out of PBS process
Migraine Australia responds to Novartis’ decision to walk away from the PBS process.
Continue ReadingPetition for a parliamentary inquiry
Sign the petition by October 16th.
Continue ReadingAimovig and Ajovy on the PBAC agenda for November
Note: Aimovig has since withdrawn from the PBS process.
Continue Reading